Diagnostic | Breast Cancer Research

Search

Posts Tagged ‘diagnostic’

Diagnostic mammography is essential to cure breast cancer

Free Online Articles Directory

Why Submit Articles?
Top Authors
Top Articles
FAQ
ABAnswers

Publish Article

0 && $.browser.msie ) {
var ie_version = parseInt($.browser.version);
if(ie_version Login

Login via

Register
Hello
My Home
Sign Out

Email

Password

Remember me?
Lost Password?

Home Page > Health > Diagnostic mammography is essential to cure breast cancer

Diagnostic mammography is essential to cure breast cancer

Edit Article |

Posted: Sep 22, 2010 |Comments: 0
|

]]>

There are lots of women who are suffering from breast cancer which has been increasing as a serious problem these days. Now you do not need to take stress further as this disease is curable. There is a treatment known as diagnostic mammography which is generally applied for women suffering from breast cancer. There are some symptoms when doctors recommend this treatment for women are as follows:

Generally there are lumps found in the breast or under arms and moreover there are changes found in skin colors like redness. Sometimes you may also come across with thickness changes found in nipple including erosion, itching, retraction etc. There may be changes in breast size such as discharge of nipples suddenly.

Besides all these symptoms, this treatment is also recommended for those who have been undergoing with any changes or abnormality on screening mammogram. Women who are facing any problem on screening mammogram are also advised for the treatment that has followed radiation therapy soon after lumpectomy first seven years.

There is a specific procedure of diagnostic mammography which begins with taking standard full sized image of breast with CC or craniocaudal. After that there is a procedure for the same treatment which is concerned with capturing side-to-side image of breast under MLO or mediolateral oblique. These are the two methods which are necessary to make out the condition of the patient. This treatment helps you in finding out morphology details, exact appearance and calcification details which are obtained through the combination of small quantity of compressions paddles with magnification technique. This technique is helpful in making out the exact picture of calcification found in females who are suffering from breast cancer or women who can suffer from this disease in future.

Micro calcification is said to be the medical term which can be considered as the initial stage of breast cancer in women. An experienced radiologist plays a vital role in diagnostic mammography as he is the only person who goes through the details and determines the result and present condition of the women suffering from breast cancer.

Retrieved from “http://www.articlesbase.com/health-articles/diagnostic-mammography-is-essential-to-cure-breast-cancer-3317000.html”

(ArticlesBase SC #3317000)

Start increasing your traffic today just by submitting articles with us, click here to get started.
Liked this article? Click here to publish it on your website or blog, it’s free and easy!

Lee Bond -
About the Author:

Lee Bond shares his views about diagnostic mammography. He is a renowned radiology expert who has over 10 years of experience in the field, and another 10 as a regular surgeon.For more information, please visit radiological therapy.

]]>

Questions and Answers

Ask our experts your Health related questions here…

Ask

200 Characters left

Does breast cancer have a cure?
What are some warning signs of breast cancer ?
What are the symptoms of breast cancer in young women?

Rate this Article

1
2
3
4
5

vote(s)
0 vote(s)

Feedback
RSS
Print
Email
Re-Publish

Source: http://www.articlesbase.com/health-articles/diagnostic-mammography-is-essential-to-cure-breast-cancer-3317000.html

Article Tags:
diagnostic mammography, radiological therapy

Imaging Diagnostic Systems Installs CT laser Mammography system in Indonesia

Imaging Diagnostic Systems Installs CT laser Mammography system in Indonesia
Imaging Diagnostic Systems, Inc., , a pioneer in laser breast imaging, announced today that it has completed installation and training for its in Jakarta, Indonesia at the Hang Lekiu Medical Center.

Aushon BioSystems and Peking University Cancer Hospital Collaboration to Focus on Predictive Diagnostic Biomarkers for …

Aushon BioSystems and Peking University Cancer Hospital Collaboration to Focus on Predictive Diagnostic Biomarkers for …
BILLERICA, Mass.–(BUSINESS WIRE)–Aushon BioSystems and Peking University Cancer Hospital Collaboration to Focus on Predictive Diagnostic Biomarkers for Liver Metastases of Colorectal Cancer

Abstracts Reporting EarlyCDT-Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection …

Abstracts Reporting EarlyCDT-Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection …
OncimmuneÂ® LLC, maker of EarlyCDTâ¢-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, today announced that two oral presentations and five poster presentations during this week’s American College of Chest Physicians’ annual meeting in Vancouver will collectively highlight the clinical and economic benefits of EarlyCDT-Lung. Â Oncimmune’s …

Read more on PR Newswire via Yahoo! Finance

Targeting Cancer Stem Cells: Therapeutic Strategies, Drug Development Pipeline, Biomarkers and Diagnostic Opportunities 2010

Cancer Stem Cell (CSC) research has accelerated in the last two years and considerable efforts are now being made to identify drug molecules that selectively target and destroy them. Today, 50 developmental molecules are being evaluated in the hope of targeting this subset of cancer cells. More than 40 companies and commercial groups are progressing these activities and around 20 drug-targeting strategies are being evaluated. Efforts are being made to target CSCs using novel single agents as well as combinations, based on new and established classes. This 2010 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising research areas in CSC characterisation. New therapeutic and diagnostic opportunities in this field are also presented.

Background: Many cancers contain a subset of stem-like cells believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs are able to “seed” new tumour formation and drive metastasis. CSCs also show resistance to a number of chemotherapy drug classes and radiotherapy – which may explain why it is difficult to completely eradicate cancer cells from the body, and why recurrence remains an ever-present threat. If these findings are confirmed in the clinic, the targeting of CSCs alongside the bulk of other cancer cells will offer a new paradigm in cancer therapeutics. Currently, there are more than 50 CSC R&D programmes in progress, around 50% of which are at Phases I-III. Patient data from the first clinical trials on CSC-targeting drugs are now being reported. More than two thirds of CSC R&D programmes are being taken forward by SME’s, and >90% of the patents in this field have been filed by Universities. Substantial opportunity for collaboration exists in this field, and this has lead to agreements between SMEs and number of international pharmaceutical companies.

Drug Pipeline: Approximately 20 different strategies, which are described in this report, are being pursued in the hope of discovering ways of selectively targeting CSCs. Recently for example, at the CTRC-AACR San Antonio Breast Cancer Symposium in December 2009, data were presented on the targeting of chemotherapy-resistant breast CSCs with the Merck compound MK-0752, a gamma-secretase inhibitor that targets the Notch pathway. In a study involving 35 women with advanced breast cancer, biopsies revealed reduced numbers of breast CSCs. In this particular case, it was suggested that combination therapies involving agents that also target the Notch pathway (believed to be important in CSC renewal) may offer more powerful strategies for killing resistant CSC populations.

Cancer Diagnostics: CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in the clinic, this will place CSCs at the heart of cancer diagnostics and biomarkers. Scientists have identified a number of surface proteins, such as CD44, CD133 and many others, that may have important utility in both of these areas. A number of intracellular markers found in CSCs may also have diagnostic utility. These developments are described in this report. For example, CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, and can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict breast and colon cancer recurrence. The adaption of these techniques, based on specific CSC phenotypes, may provide sensitive new methods for identifying CSCs in the body. If this is achieved, it will have important implications in therapeutic decision-making and monitoring.

This 2010 report gives a comprehensive and up-to-date review of global R&D on CSCs, and strategies to target them. This includes around 40 companies or commercially based research organisations (including 27 SMEs and 8 international pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, clinical trials and related areas.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3358/Targeting-Cancer-Stem-Cells-Therapeutic-Strategies-Drug-Development-Pipeline-Biomarkers-and-Diagnostic-Opportunities-2010.html

or email us your query at :

Cancer Stem Cell (CSC) research has accelerated in the last two years and considerable efforts are now being made to identify drug molecules that selectively target and destroy them. Today, 50 developmental molecules are being evaluated in the hope of targeting this subset of cancer cells. More than 40 companies and commercial groups are progressing these activities and around 20 drug-targeting strategies are being evaluated. Efforts are being made to target CSCs using novel single agents as well as combinations, based on new and established classes. This 2010 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising research areas in CSC characterisation. New therapeutic and diagnostic opportunities in this field are also presented.

Background: Many cancers contain a subset of stem-like cells believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs are able to “seed” new tumour formation and drive metastasis. CSCs also show resistance to a number of chemotherapy drug classes and radiotherapy – which may explain why it is difficult to completely eradicate cancer cells from the body, and why recurrence remains an ever-present threat. If these findings are confirmed in the clinic, the targeting of CSCs alongside the bulk of other cancer cells will offer a new paradigm in cancer therapeutics. Currently, there are more than 50 CSC R&D programmes in progress, around 50% of which are at Phases I-III. Patient data from the first clinical trials on CSC-targeting drugs are now being reported. More than two thirds of CSC R&D programmes are being taken forward by SME’s, and >90% of the patents in this field have been filed by Universities. Substantial opportunity for collaboration exists in this field, and this has lead to agreements between SMEs and number of international pharmaceutical companies.

Drug Pipeline: Approximately 20 different strategies, which are described in this report, are being pursued in the hope of discovering ways of selectively targeting CSCs. Recently for example, at the CTRC-AACR San Antonio Breast Cancer Symposium in December 2009, data were presented on the targeting of chemotherapy-resistant breast CSCs with the Merck compound MK-0752, a gamma-secretase inhibitor that targets the Notch pathway. In a study involving 35 women with advanced breast cancer, biopsies revealed reduced numbers of breast CSCs. In this particular case, it was suggested that combination therapies involving agents that also target the Notch pathway (believed to be important in CSC renewal) may offer more powerful strategies for killing resistant CSC populations.

Cancer Diagnostics: CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in the clinic, this will place CSCs at the heart of cancer diagnostics and biomarkers. Scientists have identified a number of surface proteins, such as CD44, CD133 and many others, that may have important utility in both of these areas. A number of intracellular markers found in CSCs may also have diagnostic utility. These developments are described in this report. For example, CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, and can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict breast and colon cancer recurrence. The adaption of these techniques, based on specific CSC phenotypes, may provide sensitive new methods for identifying CSCs in the body. If this is achieved, it will have important implications in therapeutic decision-making and monitoring.

This 2010 report gives a comprehensive and up-to-date review of global R&D on CSCs, and strategies to target them. This includes around 40 companies or commercially based research organisations (including 27 SMEs and 8 international pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, clinical trials and related areas.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3358/Targeting-Cancer-Stem-Cells-Therapeutic-Strategies-Drug-Development-Pipeline-Biomarkers-and-Diagnostic-Opportunities-2010.html

or email us your query at : info@visionshopsters.com
———————————————-

Aarkstore Enterprise-Womens Health Diagnostic Testing

Table of Contents :
1.0 Overview 7
1.1 Statement of Report 7
1.2 Scope of this Report 7
1.3 Methodology 8
1.4 Executive Summary 9

2.0 Introduction – Sector Overview 11
2.1 Global Diagnostic Products Industry 11

3.0 Women’s Health Testing Market Analysis in Size, Growth and Share 13
3.1 Global Women’s Health Testing Markets 13
3.1.1 Market Drivers in the Women’s Health Diagnostics Testing Sector 13
3.1.1.1 Market Segments for Women’s Health Testing 13
3.1.1.2 Key Players in the Women’s Health Diagnostics Testing Segment 14
3.1.1.3 Women’s Health Testing Sector Analysis 15
3.2 U.S. Women’s Health Testing Market 15
3.2.1 Market Overview 15
3.2.2 Diagnostic Test Categories 16
3.3 European Women’s Health Diagnostic Test Market 17
3.3.1 German Women’s Care Diagnostic Market 19
3.3.2 U.K. Women’s Care Testing Diagnostic Market 22
3.3.2.1 U.K. Market Statistics 22
3.3.2.2 U.K. Competitive Analysis 23
3.3.2.3 U.K. Market Access 24
3.3.3 French Women’s Care Diagnostic Market 25
3.3.4 Italian Women’s Care Diagnostic Market 25
3.3.5 Spanish Women’s Care Diagnostic Market 26
3.4 Japanese Women’s Care Testing Market 26
3.5 Chinese Women’s Care Market 27
3.6 Rest of the World Women’s Care Testing Market 28

4.0 Women’s Health Testing Individual Markets 30
4.1 Pregnancy Testing 30
4.2 Osteoporosis Testing 36
4.2.1 In Vitro Blood Tests 40
4.2.2 Bone Densitometry Devices 42
4.3 Prenatal Screening Testing 44
4.3.1 Cystic Fibrosis 44
4.3.2 Prenatal Genetic Testing 47
4.3.3 Fragile X Syndrome 49
4.3.4 Tay-Sachs Disease 49
4.4 Fertility Testing 49
4.5 Breast Cancer 52
4.5.1 CA 15-3 54
4.5.2 CA 27-29 54
4.5.3 BRCA1 Breast and Ovarian Cancer Gene 54
4.5.4 BRCA2 Breast Cancer Gene 54
4.5.5 Tissue polypeptide antigen (TPA) 56
4.5.6 DNA Ploidy and S-phase Fraction 56
4.5.7 Estrogen and Progesterone Receptor (ER and PR) 56
4.5.8 HER-2 56
4.5.9 HER-2 and Herceptin 57
4.5.10 p53 57
4.5.11 NMP66 57
4.5.12 Mammastatin 57
4.6 Ovarian Cancer 58
4.6.1 CA 125 II™ 58
4.6.2 Steroid Hormone Receptors 60
4.6.3 Epidermal Growth Factor Receptor (EGFR) 60
4.6.4 HER-2/neu 60
4.6.5 P53 Tumor Suppressor Gene 60
4.6.6 Lysophospholipids 60
4.7 Cervical Cancer 61
4.7.1 Pap Smears 62
4.7.2 Human Papillomavirus (HPV) Testing 65
4.8 Miscellaneous Testing 69
4.8.1 Estriol 69
4.8.2 Fetal Fibronectin (fFN) 70
4.8.3 Vaginal pH and Vaginitis 70
4.9 Human Immunodeficiency Virus (HIV) 71
4.10 Infectious Disease Testing 72
4.10.1 Strep Testing 72
4.10.2 Chlamydia 75
4.10.3 Methicillin-Resistant Staphylococcus Aurea (MRSA) 76
4.10.4 Hepatitis 77

For more information please contact :

http://www.aarkstore.com/reports/Womens-Health-Diagnostic-Testing-1340.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com

Novartis, Myriad May Get Shield for Diagnostic Tests After High Court Case

Novartis, Myriad May Get Shield for Diagnostic Tests After High Court Case
Myriad Genetics Inc. , Genomic Health Inc. and the rest of the burgeoning industry for personalized medicine stand to gain from yesterday’s landmark U.S. Supreme Court decision on patenting business methods.

Why the diagnostic for breast cancer is poor, and doctors don’t refer to right tests and don’t listen?

I have dence breast, i had discharge from breast before, and my sister had cancer.Doctors in Kaizer Permanente San Francisco didn’t refer me for diagnostic mammogram or ultrasound, only for regular mammogram.I had mam. in 2004, 2005,2006.They found differens in mm.2006 komparing 2004.
It mean, i already had cancer in 2005, but they missed it.
I had biopcy, and it was taken from 2 places.
and they have to put them in two different containers, but they puted them in one.The tecnition said, it is first time in his career.And i had to have one more biopcy.
Based on result, one MD.said, i have breast cancer, 2 tumors, another said, i have only one tumor. Surgeon said, he will cut out one tumor, because second is not tumor.I was begging him to take out both, and hi did it.The second one turn out was a tumor, too.Surgeon said it happen first time in his career.And i had second surgery for second tumor.I had one unnesessery biopcy and one unnessesery surgery. Doctors should pay attention

Breast Cancer: Screening vs. Diagnostic Mammograms

What’s the difference between a screening and diagnostic mammogram? View the videos in the www.healthchoices.ca medical video library, featuring Dr Ian Gardiner, Director of Advanced Breast Imaging Program at Canada Diagnostic Centres in Vancouver,

I have two lumps on my right breast. Went to doctor and will have a diagnostic mammogram done but in 5 weeks?

I am 32 and the next available appointment at the hospital i have the order to go to is not until May 18. Isn’t that too long away? I am high risk for breast cancer, my mother was diagnosed with breast cancer at 42 and died at 52. I also have pain in the chest area. I am very worried, what if my time is running out to catch this at an early stage.

February 2012
M	T	W	T	F	S	S
« Nov
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29

Posts Tagged ‘diagnostic’

Calendar

Categories

Tag Cloud